- Home
- LNKB vs AARD Comparison
LNKB vs AARD Comparison
Compare LNKB & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNKB | AARD |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.2M | 281.1M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | LNKB | AARD |
|---|---|---|
| Price | $8.30 | $3.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | N/A | ★ $19.63 |
| AVG Volume (30 Days) | 91.2K | ★ 487.6K |
| Earning Date | 04-27-2026 | 03-23-2026 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | ★ 26.76 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $186,504,000.00 | N/A |
| Revenue This Year | $10.18 | N/A |
| Revenue Next Year | $9.33 | $2,107.17 |
| P/E Ratio | $9.22 | ★ N/A |
| Revenue Growth | ★ 11.29 | N/A |
| 52 Week Low | $6.09 | $3.35 |
| 52 Week High | $9.59 | $17.94 |
Technical Indicators
Market Signals| Indicator | LNKB | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 21.26 |
| Support Level | $8.07 | N/A |
| Resistance Level | $9.02 | $6.19 |
| Average True Range (ATR) | 0.21 | 0.42 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 49.06 | 11.48 |
Price Performance
Historical ComparisonAbout LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.